Welcome to our dedicated page for Celanese Del news (Ticker: CE), a resource for investors and traders seeking the latest updates and insights on Celanese Del stock.
Celanese Corporation (NYSE: CE) is a global specialty materials and chemical company that regularly issues news and updates related to its operations, financial performance and strategic decisions. The company describes itself as a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Its news flow reflects both its role in the basic organic chemical manufacturing industry and its position as a Fortune 500 company.
Investors following Celanese news can expect frequent announcements on earnings and investor communications. The company issues press releases and hosts conference calls and webcasts to discuss quarterly financial results, as seen in its announcement of a fourth quarter earnings conference call and related 8-K filings. Celanese also participates in investor events, including fireside chats with financial institutions, where its President and Chief Executive Officer presents to investors and analysts.
Celanese news also covers capital structure and financing activities. Recent releases describe registered offerings of senior notes by its subsidiary Celanese US Holdings LLC, the pricing and upsizing of those offerings, and cash tender offers for existing senior notes due in 2027 and 2028. Related updates explain how proceeds are used to repay borrowings under a term loan credit agreement, fund tender offers and support general corporate purposes.
Operational and portfolio developments appear in the company’s news as well. Celanese has announced the intended closure of an acetate tow production facility in Lanaken, Belgium, to streamline production costs, and the signing of a purchase and sale agreement to divest its Micromax® portfolio of products. Other news highlights sustainability-related milestones, such as achieving ISCC Carbon Footprint Certification for certain POM ECO-C grades at production sites in Frankfurt, Germany, and Bishop, Texas, reflecting the company’s stated focus on responsible material management and sustainable products.
By monitoring Celanese news, readers can track updates on governance changes, such as Board member resignations, sustainability initiatives, financing transactions and scheduled earnings events that shape the company’s strategic direction.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Celanese Corporation (NYSE: CE) has announced a quarterly cash dividend of $0.70 per share on its common stock. This dividend will be payable on May 15, 2023, to stockholders of record as of May 1, 2023. Celanese is a global leader in specialty materials and chemical production, with a workforce of approximately 13,000 employees worldwide and reported net sales of $9.7 billion in 2022. The company utilizes its extensive chemistry and technology expertise to create value across various industries and consumer applications.
Celanese Corporation (NYSE: CE) has announced a conference call to discuss its first quarter 2023 results on May 10, 2023, at 10:00 a.m. Eastern time. The earnings press release will be distributed after market close on May 9, 2023. Investors can access the call via webcast or by phone, with a dial-in number of 1-877-407-0989 for domestic participants. A replay will be available from May 10 to May 24, 2023. Celanese reported net sales of $9.7 billion in 2022 and continues to strengthen its position as a leader in the chemical industry.
Celanese (NYSE: CE) has announced a partnership with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for the iDose® TR intraocular implant. This device aims to lower intraocular pressure in patients with glaucoma by providing continuous, long-duration therapy, addressing issues of patient non-adherence to topical medications. Glaukos submitted a New Drug Application for iDose TR in February 2023, pending FDA approval. The collaboration is aimed at enhancing patient treatment options in ophthalmology, leveraging the proven performance of Celanese's VitalDose technology, which has a solid history of controlled-release applications.
FAQ
What is the current stock price of Celanese Del (CE)?
What is the market cap of Celanese Del (CE)?
